RHL Group LLC Makes New Investment in Merck & Co., Inc. $MRK

Key Points

• RHL Group LLC opened a new position in Merck during the fourth quarter, buying 17,995 shares valued at about $1.89 million. The stake now represents roughly 1.5% of RHL Group’s holdings and is its 10th-largest position.
• Merck is seeing positive oncology momentum, including encouraging late-stage lung cancer data for a Keytruda combination and a favorable EU CHMP opinion for Keytruda plus Padcev in bladder cancer. These developments could help expand Merck’s cancer franchise as it faces future Keytruda patent pressure.
• The company recently beat quarterly earnings and revenue expectations, reporting EPS of -$1.28 versus -$1.47 expected and revenue of $16.29 billion versus $15.85 billion forecast. Despite some weakness in Gardasil sales, analysts still rate the stock Moderate Buy with an average target price of $128.18.

RHL Group LLC acquired a new position in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 17,995 shares of the company's stock, valued at approximately $1,894,000. Merck & Co., Inc. comprises about 1.5% of RHL Group LLC's holdings, making the stock its 10th biggest holding.

Other large investors also recently modified their holdings of the company. D.A. Davidson & CO. lifted its position in shares of Merck & Co., Inc. by 4.4% during the fourth quarter. D.A. Davidson & CO. now owns 576,959 shares of the company's stock worth $60,731,000 after purchasing an additional 24,576 shares in the last quarter. Farther Finance Advisors LLC lifted its position in shares of Merck & Co., Inc. by 48.9% during the fourth quarter. Farther Finance Advisors LLC now owns 97,818 shares of the company's stock worth $10,296,000 after purchasing an additional 32,114 shares in the last quarter. Coldstream Capital Management Inc. lifted its position in shares of Merck & Co., Inc. by 12.7% during the third quarter. Coldstream Capital Management Inc. now owns 123,366 shares of the company's stock worth $10,364,000 after purchasing an additional 13,940 shares in the last quarter. NEOS Investment Management LLC lifted its position in shares of Merck & Co., Inc. by 39.9% during the third quarter. NEOS Investment Management LLC now owns 347,684 shares of the company's stock worth $29,181,000 after purchasing an additional 99,074 shares in the last quarter. Finally, Campbell Capital Management Inc. acquired a new position in shares of Merck & Co., Inc. during the third quarter worth approximately $1,866,000. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck and partner Sichuan Kelun-Biotech reported encouraging late-stage lung cancer data for a Keytruda combination, with the treatment beating Keytruda alone and improving confidence in Merck’s cancer pipeline. Kelun, Merck's lung cancer combo improves survival in late-stage China trial
• Positive Sentiment: The European Medicines Agency’s CHMP issued a positive opinion for Keytruda plus Padcev as a perioperative treatment for certain bladder cancer patients, which could expand the drug pair’s commercial reach if formally approved. Merck Receives Positive EU CHMP Opinion for KEYTRUDA Plus Padcev
• Positive Sentiment: Additional coverage highlighted positive EU recommendations and trial momentum across Merck’s oncology portfolio, suggesting the company is building new growth drivers ahead of future Keytruda patent pressure. Merck stock jumps as Keytruda combo trials boost cancer pipeline
• Neutral Sentiment: Some commentary noted Gardasil sales remain weak due to soft demand in China and other markets, which is a reminder that Merck still has headwinds outside oncology. Will Weak Gardasil Sales Continue to Ail MRK's Vaccines Sales in 2026?
• Neutral Sentiment: Merck’s recent run-up also reflects broader investor optimism after strong quarterly results and improving sentiment around its pipeline, rather than a single one-day event. Merck Stock Climbs on Cancer Data. Why the Drugmaker Is More Than a One-Trick Pony.

Merck & Co., Inc. Trading Up 0.1%

Shares of NYSE MRK opened at $122.55 on Monday. The company's 50 day simple moving average is $115.92 and its 200 day simple moving average is $110.41. Merck & Co., Inc. has a fifty-two week low of $75.40 and a fifty-two week high of $125.14. The firm has a market capitalization of $302.67 billion, a P/E ratio of 34.52, a P/E/G ratio of 2.76 and a beta of 0.18. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, beating the consensus estimate of ($1.47) by $0.19. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The business had revenue of $16.29 billion for the quarter, compared to analyst estimates of $15.85 billion. During the same period in the prior year, the business posted $2.22 earnings per share. Merck & Co., Inc.'s revenue was up 4.9% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, analysts predict that Merck & Co., Inc. will post 5.16 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on MRK shares. Weiss Ratings lowered shares of Merck & Co., Inc. from a "hold (c+)" rating to a "hold (c)" rating in a research report on Friday, May 15th. Guggenheim upped their target price on shares of Merck & Co., Inc. from $122.00 to $140.00 and gave the stock a "buy" rating in a research report on Friday, February 6th. JPMorgan Chase & Co. upped their target price on shares of Merck & Co., Inc. from $125.00 to $135.00 and gave the stock an "overweight" rating in a research report on Monday, April 6th. Wells Fargo & Company cut their price objective on shares of Merck & Co., Inc. from $150.00 to $145.00 and set an "overweight" rating on the stock in a report on Friday, May 1st. Finally, Wall Street Zen lowered shares of Merck & Co., Inc. from a "buy" rating to a "hold" rating in a report on Saturday, May 16th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and seven have given a Hold rating to the stock. Based on data from MarketBeat.com, Merck & Co., Inc. presently has an average rating of "Moderate Buy" and an average target price of $128.18.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.